#United States #New York #Securities Class Action #Boston Scientific #Faruqi & Faruqi

Boston Scientific Class Action Update

Faruqi & Faruqi, LLP is actively informing investors about a significant upcoming deadline related to Boston Scientific Corporation. If you purchased Boston Scientific stocks between July 23, 2025, and February 3, 2026, it's vital to note that the deadline to be part of a securities class action is approaching on May 4, 2026.

Background of the Case

The law firm is currently investigating potential claims against Boston Scientific due to allegations that the company and its executives may have violated federal securities laws. This stems from claims of disseminating false information about the performance of their Electrophysiology (EP) segment. The complaint suggests that the firm's management was aware of the unsustainable growth rate within this segment, contrary to public communications that suggested strong and consistent growth.

On February 4, 2026, Boston Scientific disclosed disappointing results for its fourth quarter and the whole year of 2025, revealing a significant drop in U.S. EP sales. The company attributed these results to a mixture of slower market growth and heightened competition, diverging sharply from their prior optimistic assessments. Following this announcement, the stock suffered a sharp decline of 17.6%, resulting in a loss of $16.12 per share, which adversely affected investors.

Legal Implications for Investors

The class action stipulates that an appointed lead plaintiff will be someone who possesses the largest interest in the financial relief sought in the lawsuit. This lead plaintiff will oversee the litigation process. Any potential class member has the option to either apply to be a lead plaintiff through their attorney or remain in the group without actively participating.

Notably, your chances of receiving any financial recovery won't be diminished by whether you decide to be a lead plaintiff or not. If you possess information related to Boston Scientific’s conduct during the relevant period, such as being a whistleblower, a former employee, or a shareholder, your input could be valuable.

Faruqi & Faruqi encourages all interested parties to reach out to the firm directly. For more information regarding the Boston Scientific class action, interested individuals can visit the Faruqi & Faruqi website or contact Senior Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

The impending deadline for the class action is critical for all investors who have been affected by Boston Scientific’s recent performance. With significant stakes on the line, timely participation could influence the outcome of the claims being brought forth. It is advisable to consult legal expertise to explore potential avenues for recovery, especially as the legal landscape can be complex and nuanced. Stay informed and proactive in safeguarding your investment interests.